World Health Organization Sounds Alert Over Severe Shortage of Weight-Loss Injections

Less than one in 10 individuals that would benefit from obesity jabs like Wegovy can access them, states the World Health Organization as it releases its first guidance on the drugs.

With over a billion individuals worldwide currently classified as obese, it is calling for more widespread and fairer access to this class of drugs.

Based on forecasts, in excess of 2,000,000,000 are projected to be obese by 2030 if no action is taken.

"The new guidance recognises that excess weight is a long-term condition that can be treated with thorough and continuous care," stated its chief Tedros Adhanom Ghebreyesus.

Significant expense, limited production capacity, and logistical bottlenecks are significant obstacles to universal access to the jabs that can aid individuals in losing considerable body mass, says the body.

Weight-Loss Drug Shortage

Despite the present best projected outlook, the supply of these medications could only cover approximately 100 million people – less than 10% of the global need, according to the health organization.

The advice calls on nations and manufacturers to increase access, via measures including patent sharing.

A patent on the active ingredient – the main component of a leading brand – is scheduled to end in a number of nations in 2026.

The Way Obesity Jabs Work

The injections replicate a natural hormone to delay gastric emptying, suppress the appetite and boost feelings of fullness so individuals eat less.

People commonly see weight reduction within a few weeks of beginning the regular doses.

Evidence indicates users may regain a significant portion a year later of halting the treatment, because their normal hunger return.

To be carrying excess weight elevates your chance for developing medical conditions, including diabetes, heart disease, brain attack, and specific malignancies.

Obesity affects people in countries worldwide and was responsible for over three and a half million deaths worldwide in 2024, as per the health agency.